Analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will report ($0.20) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Corvus Pharmaceuticals’ earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.22). Corvus Pharmaceuticals posted earnings per share of ($0.35) in the same quarter last year, which suggests a positive year-over-year growth rate of 42.9%. The business is expected to issue its next quarterly earnings report on Thursday, March 24th.
On average, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($1.06) to ($0.88). For the next year, analysts expect that the firm will post earnings of ($0.79) per share, with EPS estimates ranging from ($1.05) to ($0.64). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Sunday, October 31st. The company reported ($0.24) EPS for the quarter, hitting analysts’ consensus estimates of ($0.24).
CRVS has been the topic of several recent analyst reports. Zacks Investment Research cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 5th. Cantor Fitzgerald lifted their target price on shares of Corvus Pharmaceuticals from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, December 3rd. Finally, Jefferies Financial Group initiated coverage on shares of Corvus Pharmaceuticals in a report on Wednesday, December 1st. They issued a “buy” rating and a $8.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $5.55.
This could be the most profitable event in crypto history. And it only happens once. If you miss it, there are no second chances.
Corvus Pharmaceuticals stock traded up $0.08 during midday trading on Friday, reaching $2.73. 535,968 shares of the company’s stock were exchanged, compared to its average volume of 2,591,556. Corvus Pharmaceuticals has a 52 week low of $1.86 and a 52 week high of $9.54. The stock’s 50-day simple moving average is $3.76 and its 200 day simple moving average is $3.36. The firm has a market cap of $127.08 million, a price-to-earnings ratio of 45.50 and a beta of 0.95.
In other news, major shareholder Ecor1 Capital, Llc sold 3,000,000 shares of the business’s stock in a transaction that occurred on Thursday, September 30th. The shares were sold at an average price of $5.04, for a total transaction of $15,120,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 45.12% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CRVS. Zacks Investment Management bought a new stake in Corvus Pharmaceuticals during the third quarter valued at approximately $48,000. Lindbrook Capital LLC bought a new stake in Corvus Pharmaceuticals during the third quarter valued at approximately $68,000. Natixis grew its position in Corvus Pharmaceuticals by 69.1% during the second quarter. Natixis now owns 27,900 shares of the company’s stock valued at $74,000 after buying an additional 11,400 shares during the period. State Street Corp bought a new stake in Corvus Pharmaceuticals during the second quarter valued at approximately $79,000. Finally, Squarepoint Ops LLC bought a new stake in Corvus Pharmaceuticals during the third quarter valued at approximately $97,000. 66.66% of the stock is owned by hedge funds and other institutional investors.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors.
Read More: Hang Seng Index (HSI)
Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Corvus Pharmaceuticals right now?
Before you consider Corvus Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Corvus Pharmaceuticals wasn’t on the list.
While Corvus Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: -$0.20 EPS Expected for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) This Quarter